EZH2 and diffuse large B-cell lymphoma: VHL-targeting YM181 (55) and YM281 (56) potently degraded EZH2 with substantial selectivity over EZH1 and inhibited proliferation in both diffuse large B-cell lymphoma (DLBCL) and other lymphoma subtypes outperforming EPZ6438 that was only effective against DLBCL.